Origene Collaborating with PROOF Centre on Protein Diagnostics for Heart and Kidney Transplants | GenomeWeb

Canada's Centre of Excellence for the Prevention of Organ Failure – also called the PROOF Centre – has partnered with Origene Technologies on blood-based protein assays for monitoring heart and kidney transplantation.

The agreement covers a multi-year project that aims to provide monitoring and predictive blood tests for heart and kidney transplant patients. Origene will use its experience in monoclonal antibody production and Luminex multiplex assay development to build and implement diagnostic assays for transplant care, the company said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.